Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast, Q2 2020

2020-09-30
Price :
Published : Sep-2020
No. of Pages : 39
Table of Contents
1 COVID-19 Global Analyst Consensus
1.1 COVID-19 Drugs with Global Analyst Consensus Sales Forecast
1.2 COVID-19 Global Analyst Consensus Sales Forecast
1.3 Top Three COVID-19 Drugs with Peak Forecast: Global Analyst Consensus Sales Forecasts
2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts
2.1 COVID-19 Prophylactic Vaccine Global Analyst Consensus Sales Forecast
2.2 COVID-19 Therapeutic Drugs: Global Analyst Consensus Sales Forecasts
3 Gilead Sciences
3.1 Global Analyst Consensus Sales Forecast - remdesivir
3.2 Percentage Change from Q2 to Q3 2020 Global Analyst Consensus Sales Forecast- Remdesivir
4 Inovio Pharmaceuticals
4.1 Global Analyst Consensus Sales Forecast - INO-4800
4.2 Percentage Change from Q2 to Q3 2020 Global Analyst Consensus Sales Forecast - INO-4800
5 CanSino Biologics
5.1 Global Analyst Consensus Sales Forecast - COVID-19 vaccine
5.2 Percentage Change from Q1 to Q2 2020 Global Analyst Consensus Sales Forecast - COVID-19 Vaccine
6 Moderna
6.1 Global Analyst Consensus Sales Forecast - mRNA-1273
6.2 Percentage Change from Q2 to Q3 Global Analyst Consensus Sales Forecast - mRNA-1273
7 Regeneron Pharmaceuticals
7.1 Global Analyst Consensus Sales Forecast - REGN-COV2
8 Key Findings
9 Appendix
9.1 Methodology
9.2 Related Reports
9.3 About the Authors
9.4 About GlobalData
9.5 Contact Us
Filed in: Pharmaceutical
Publisher : GlobalData